Fu, Dun Jack http://orcid.org/0000-0003-2852-6912
Lipkova, Veronika
Liefers, Bart
Glinton, Sophie
Faes, Livia
McKeown, Alex
Scheibler, Lukas
Pontikos, Nikolas
Patel, Praveen J.
Zhang, Gongyu
Keane, Pearse A.
Balaskas, Konstantinos
Funding for this research was provided by:
Moorfields Eye Charity Career Development Award (R190031A, R190028A)
Moorfields Eye Charity Grant (GR001003)
Wellcome Trust Grant (206619_Z_17_Z)
UK Research & Innovation Future Leaders Fellowship (MR/T019050/1)
Article History
Received: 26 June 2023
Accepted: 15 August 2023
First Online: 16 September 2023
Declarations
:
: Nikolas Pontikos: Moorfields Eye Charity Career Development Award (R190031A), equity owner, Phenopolis Ltd. Dun Jack Fu: Consulting for Abbvie, Allergan, DeepMind. Livia Faes: Nothing to declare. Gongyu Zhang: No conflicts of interest. Bart Liefers: No conflicts of interest. Sophie Glinton: Moorfields Eye Charity Grant (GR001003), Wellcome Trust Grant (206619_Z_17_Z). Veronika Lipkova: No conflicts of interest. Praveen J Patel: Consulting for Roche, Novartis, Bayer and Boeringher Ingelheim; speaker fees from Bayer and Roche. Pearse A Keane: Moorfields Eye Charity Career Development Award (R190028A), UK Research & Innovation Future Leaders Fellowship (MR/T019050/1); Consulting for DeepMind, Roche, Novartis, Apellis and BitFount; equity owner in Big Picture Medical; speaker fees from Heidelberg Engineering, Topcon, Allergan and Bayer. Konstantinos Balaskas: Speaker fees from Novartis, Bayer, Alimera, Allergan and Heidelberg; consulting fees from Novartis and Roche and research support from Apellis, Novartis and Bayer. Alex McKeown: Employee of Apellis. Lukas Scheibler: Employee of Apellis.
: This study involves human participants who were enrolled as patients at 46 sites in the USA (New England Institutional Review Board, University of Miami, Mayo Clinic, Institutional Review Board of the Cleveland Clinic Foundation, Duke University Health System Institutional Review Board, and Research Compliance Office Stanford University), Australia (Bellberry Ltd), and New Zealand (Northern A Health and Disability Ethics Committee, Health and Disability Ethics Committees, and Ministry of Health). The study was performed in accordance with the tenets of the Declaration of Helsinki, International Conference on Harmonisation Good Clinical Practice guidelines and all applicable regulations. Institutional review board or ethics committee approval was obtained at each site. All patients provided written informed consent. For more information please visit ClinicalTrials.gov using the following identifier: NCT02503332. This is a post hoc study and the full details of institutions involved is attached to the original FILLY trial. No additional data was collected for this post hoc analysis.